Global Transdermal Drug Delivery Systems Market was valued around US$ XX Mn by 2018 and growing at a significant CAGR over seven years forecast period 2019-2025

Global Transdermal Drug Delivery Systems Market was Valued at US$ XX Mn in 2018, Due to Rise in Prevalence of Chronic Diseases and Advancements in Techology in TDDS
Analyst Speak:

“The Global Transdermal Drug Delivery Systems Market was valued around US$ XX Mn by 2018 and growing at a significant CAGR over seven years forecast period 2019-2025” due to the advantages of TDDS such as high bioavailability and very few side effects and increase in prevalence of chronic diseases and technological advancements in TDDS.

The Global transdermal drug delivery systems market was valued at US$ XX Mn in 2018 and growing at a significant CAGR over the forecast period due to aging population and growing adoption to new drug delivery systems are major driving factors of the market over the forecast period. Moreover, rise in R&D activities and advancements in technology boosts the growth of the market. However, irritation and edema and other disadvantages such as natural restriction of drug entry imposed by the skin permeability and adoption and compatibility of large sized drugs is expected to hinder the growth of the market.

A sample of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/transdermal-drug-delivery-systems-market/#ulp-4H8Z4LpNMLEuOnnx

Global transdermal drug delivery systems market segmented on the basis of application and technology.

Pain Management Segment, by Application Type Leads the Transdermal Drug Delivery Systems Market with highest revenue share

Based on application type, global transdermal drug delivery systems market is segmented into cardiovascular, contraception, pain management & neurological disorders, smoking cessation, and others. Pain management segment registered highest revenue share in 2018 and expected to dominate over the forecast period owing to rising burden of chronic pain across the world and availability of transdermal products boosts the growth of the market.
North America Dominates the Global Transdermal Drug Delivery Systems Market

PBI’s Global transdermal drug delivery systems market report analyses the market in different countries such as North America, Europe, Asia Pacific, Latin America, and Middle East Africa. According to geographical analysis, North America dominates the revenue share in 2018 and the same trend is projected to follow over 2019-2025 due to increase in prevalence of targeted diseases such as cardiovascular diseases, central nervous system disorders, and chronic pain etc. drives the growth of the market over forecast years.

To view TOC of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/transdermal-drug-delivery-systems-market/#ulp-c654SbFYO64MsOhu

Strategic Partnerships, Acquisitions and Mergers Among the Market Players and Launch of New products and Technologies are the key strategies adopted by the market players

Market Players are increasingly adopting the strategies such as strategic partnerships, acquisitions, and mergers among the market players and launch of new products and advanced technology based products to enhance their revenue and strengthen their position in the market. For instance, In July 2018, UCB (Belgium) received the Import Drug License (IDL) for its transdermal rotigotine patch—NEUPRO from the China Food and Drug Administration (CFDA). In January 2018, Hisamitsu Pharmaceutical (Japan) launched ALLESAGA TAPE in the Japanese market.

Key player’s profiles in the report are Novartis AG (Switzerland), Boehringer Ingelheim GmbH (Germany), Generex Biotechnology Corp. (Canada), Echo Therapeutics, Inc. (U.S.), Crescita Therapeutics Inc (Canada), MedPharm (U.K.), Pantec Biosolutions AG (Liechtenstein), Transdermal Corp. (U.S.), Noven Pharmaceuticals, Inc. (U.S.), Actelion Pharmaceuticals Ltd (Switzerland), Johnson & Johnson Limited (U.S.), 3M Pharmaceuticals Inc. (U.S.), Mylan Pharmaceuticals Inc. (U.S.), and GlaxoSmithKline plc (U.K.).

Precision Business Insights (PBI) in its report titled “Global Transdermal Drug Delivery Systems Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2018 and Forecast 2019-2025” assesses the market performance over seven years forecast period over 2019-2025. The report analyses the market value forecast and provides the strategic insights into the market driving factors, challenges that are hindering the market revenue growth over forecast period.

Need more information about this report @
https://www.precisionbusinessinsights.com/market-reports/transdermal-drug-delivery-systems-market/#ulp-14mlyhjMGhVjZqa3

Detailed Segmentation

By Application
o Cardiovascular
o Contraception
o Pain Management / Neurological Disorders
o Smoking Cessation
o Others
By Technology
o Electric Current
o Electroporation
o Radio Frequency
o Thermal
o Ultrasound
o Others
Country

o Germany
o France
o U.K.
o Italy
o Spain
o Russia
o Poland
o Rest of Europe

Get access to full summary @
https://www.precisionbusinessinsights.com/market-reports/transdermal-drug-delivery-systems-market/

About Precision Business Insights
Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.

Contact to Precision Business Insights,

Kemp House,
152 – 160 City Road,
London EC1V 2NX
Email: sales@precisionbusinessinsights.com
Toll Free (US): +1-866-598-1553
Website @ https://www.precisionbusinessinsights.com

This release was published on openPR.